Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1306 to 1320 of 2184 results for guidelines

  1. Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)

    Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Last updated
    21 May 2024
    View recommendations

    Sections for TA312

  2. What is the comparative effectiveness and cost effectiveness of exercise referral schemes compared with other interventions that aim to help people to become more physically active? Relative effectiveness and cost effectiveness should be compared in controlled trials.

    doing some physical activity, albeit below current UK physical activity guidelines rather than none at all, should be taken into...

    Research recommendation
    Published
    9 June 2015

  3. What factors encourage under-represented groups to participate in and complete an exercise referral scheme? What factors prevent these groups from participating? Under-represented groups include: people from black and minority ethnic groups, people with disabilities and those from lower socioeconomic groups.

    doing some physical activity, albeit below current UK physical activity guidelines rather than none at all, should be taken into...

    Research recommendation
    Published
    9 June 2015

  4. What factors encourage uptake of, and adherence to, an exercise referral scheme? Factors to consider include: design, content and delivery; referral mechanisms; choice of activity; qualifications and cost of instructors. Also identify any barriers preventing participation and factors that encourage it.

    doing some physical activity, albeit below current UK physical activity guidelines rather than none at all, should be taken into...

    Research recommendation
    Published
    9 June 2015

  5. What interventions are effective and cost effective in supporting return to work, in all workplaces including micro-, small- and medium-sized organisations, after long-term sickness absence in the UK?

    or planning a return to work are treated consistently.The focus of this guideline is on managing sickness absence among all employees,...

    Research recommendation
    Published
    10 February 2020

  6. iFuse for treating chronic sacroiliac joint pain (HTG488)

    Evidence-based recommendations on iFuse for treating chronic sacroiliac joint pain.

    HealthTech guidance
    Last updated
    30 August 2022
    View recommendations

    Sections for HTG488

  7. Neuropad for detecting preclinical diabetic peripheral neuropathy (HTG486)

    Evidence-based recommendations on Neuropad for detecting preclinical diabetic peripheral neuropathy.

    HealthTech guidance
    Last updated
    21 September 2022
    View recommendations

    Sections for HTG486

  8. Living-donor liver transplantation (HTG390)

    Evidence-based recommendations on living-donor liver transplantation. This involves replacing a diseased or damaged liver with a healthy one from a living human donor.

    HealthTech guidance
    Published
    25 November 2015
    View recommendations

    Sections for HTG390

  9. Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (TA902)

    Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.

    Technology appraisal guidance
    Published
    21 June 2023
    View recommendations

    Sections for TA902

  10. Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide (ES5)

    Summary of the evidence on oral glycopyrronium bromide for severe sialorrhoea (drooling) in children and young people with chronic neurological disorders

    Evidence summary
    Published
    14 February 2017

  11. Insertion of a magnetic bead band for faecal incontinence (HTG336)

    Evidence-based recommendations on insertion of a magnetic-bead band for faecal incontinence. This involves placing a ring of magnetic beads into a tunnel made around the anus to prevent incontinence.

    HealthTech guidance
    Published
    27 March 2014
    View recommendations

    Sections for HTG336

  12. Baseline FDG-PET-CT imaging for people with diffuse large B-cell lymphoma stage II or above:- In people with diffuse large B-cell lymphoma stage II or above, does a baseline FDG-PET-CT scan have any advantages over a baseline CT scan in the correct interpretation of the end-of-treatment FDG-PET-CT scan?

    notes(if applicable) Why this is important:- A number of consensus-based guidelines and a body of clinical opinion advocate baseline...

    Research recommendation
    Published
    25 August 2016

  13. ReStore Soft Exo-Suit for gait rehabilitation (MIB239)

    NICE has developed a medtech innovation briefing (MIB) on ReStore Soft Exo-Suit for gait rehabilitation .

    Medtech innovation briefing
    Published
    15 December 2020

  14. EarlySense for heart and respiratory monitoring and predicting patient deterioration (MIB49)

    NICE has developed a medtech innovation briefing (MIB) on EarlySense for heart and respiratory monitoring and predicting patient deterioration

    Medtech innovation briefing
    Published
    22 January 2016

  15. Decreasing pharmacological treatment:- In adults, young people and children with well-controlled asthma, what are the objective measurements and prognostic factors that indicate that a decrease in regular maintenance treatment is appropriate?

    applicable) Why this is important:- There is consensus within the guideline committee and across healthcare professionals managing...

    Research recommendation
    Published
    18 October 2018